Flamingo Therapeutics NV
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Flamingo Therapeutics NV - overview
Established
2020
Location
Leuven, -, Belgium
Primary Industry
Biotechnology
About
Based in Belgium, and founded in 2020, Flamingo Therapeutics NV operates as an RNA (ribonucleic acid) therapeutics company. The company was founded by VIB, Ghent University, KU Leuven, the University of Michigan, Kurma Partners, and PMV. In March 2023, Dynacure SA, a portfolio company of Andera Partners, CDC Enterprises, Perceptive Advisors, and Tekla Capital Management, agreed to merge with Flamingo Therapeutics and will continue to operate under the Flamingo Therapeutics brand. As of 2023, the company’s president and CEO is Stéphane van Rooijen.
Flamingo Therapeutics offers a drug development platform, which is a biotech platform that develops RNA-based therapeutics for cancer patients. The company’s pipeline programs include Danvatirsen, a drug that targets STAT-3, and FTX-001, a drug that targets MALAT1. In addition, the company provides FLAME (Flamingo LncRNA Antisense Mining Engine), which is a long non-coding RNA platform that develops drugs for diseases like cancer.
Current Investors
PMV, Kurma Partners, CDC Enterprises
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.flamingotx.com
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Flamingo Therapeutics NV - financials
| Fiscal Year Ended | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - |
| EBITDA (USD) | (981,292) | (260,988) | (695,544) | - | - | - |
| Operating Income (USD) | (1,207,409) | (2,409,768) | (7,386,206) | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - |
| NET Income (USD) | (1,142,597) | (2,417,249) | (7,341,353) | - | - | - |
| % Net Margin | - | - | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.